**Background**

Traumatic brain injury (TBI) can lead to necrosis, apoptosis and autophagic cell death of neurons following by multiple events such as opening of the blood-brain or blood-spinal cord barrier, inflammation, edema, ecotoxicity, increase in free-radicals, altered cell signaling and gene expression The microenvironment of the injured brain includes different cell types such as normal and dysfunctional neurons (surviving bodies and dead axons or synapses), denervated intact neurons, senescent cells, blood capillaries, glial scars, free-radicals, neuroinflammatory and neurotrophic factors, and the extra-cellular matric. Thus, the repair and reconstruction of the brain tissue is the ultimate goal for the treatment of brain injury. It has been observed that after injury, the brain may be attempting to repair itself, endogenous neural stem cells (NSCs) can migrate from the subventricular zone (SVZ), dentate gyrus (DG), and striatum to the injury site where they differentiate into neurons, oligodendrocytes, and astrocytes. Axon formation is a critical step to neural connection and synaptogenesis. Axon can grow and sprout from new neurons derived from NSCs. However, the spontaneous regenerative process is not sufficient for complete reconstruction and full recovery of the neuronal function (and in general in adult brain, regeneration and migration of new neurons is limited).

Also, as part of the acute injury response, glial cells (astrocytes and microglia) migrate to the injury site where they form the reactive glial scars to repair BBB, SCB and isolate the site of injury and helps in the healing process. However, the same cells start producing inhibiting growth factors limiting axonal regeneration.

Therefore, the design of neural injury response strategy needs to promote favorable factors and simultaneously inhibit adverse factors.

Cell transplantation therapy has great potential and, following cell delivery using intravenous and intraarterial injections after TBI, significant neurological improvements are observed. However transplanting stem cells in-vivo is a complex and difficult operation: 1) these cells have low capacity of migration and tend to form clusters close to the targeted site and 2) they have to integrate into the host neuronal network and survive; overall this process of migration, differentiation and integration has yet to be fully understood.

Direct cell reprogramming, or transdifferentiation, is the conversion, using typically defined transcription factors (TFs), of a somatic cell into another without inducing pluripotency. For both techniques, the main concerns are risk of tumor formation, and spread of foreign new derived neurons in unintended sites, however cell transplantation is a more involved process with a risk of triggering an immune-rejection from the host and comes with a high-cost involved in clinical grade cell production for transplantation. Yet direct reprogramming in-vivo still faces difficulties which need to be addressed:

1. Careful selection of the target cell for reprogramming to avoid depletion of the cells being reprogrammed: cells to be reprogrammed need to be carefully selected as not to impair their functional role.
2. Identify transcription factors (TFs) which promote conversion to identified neuronal cells.
3. Design of a precise and safe gene delivery system.

In the study we will address each of these points.

Design of an efficient and specific strategy which promotes reprogramming of astrocytes to neuroblasts in the adult brain after TBI with a low-risk gene delivery system.

Wenze Niu et al., in their study, selected astrocytes for cell reprogramming since they are one of the most abundant non-neuronal cells in the CNS. And following a TBI, they aggregate to form glial scars which physically and chemically obstruct axonal regeneration. Among the eight TFs (SCLA1, BRN2, KLF4, MYC, MYT1L, OCT4, SOX2 and ZFP521) and the four microRNAs (miR9, miR124, miR125 and miR128), they found that SOX2, by itself, induces the most significant number of DCX+ cells, adult neuroblast cells (iANBs). Next, they crossed various transgenic mice with reporter-line mice, and subsequently injected them with SOX2-expressing lentivirus. They showed that 1) iANBs were only localized in the injected striatal regions and were not the result of any migration of DCX+ cells coming from areas surrounding the injection site like the lateral ventricle, 2) the iANBs originated from resident astrocytes, and 3) the iANBs originated from the cells transduced by lentivirus under hGFAP promoter and not from IBA1+ microglia or N2-glia. Additionally, they also proved that SOX-2 induced iANBS did not originate from neurons going through dedifferentiation and becoming DCX+ neuroblasts. Then they investigated iANBs characteristics demonstrating that the neuroblasts derived from non-dividing astrocytes and passed through a proliferating state. Finally, after co-injecting BNDF-Nog-expressing lentivirus with SOX2-lentivirus, the researchers performed a whole-cell patch-clamp which exhibited mature neurons with full electrophysiological function. In the course of the experiments, they did not observe any tumor formations confirming that the newly converted neurons have been successfully integrated into the local neuronal network without immediate side-effects.

Research from Nui et al., identified SOX2 as a critical transcription factor in the induction of resident astrocytes to neuroblasts, in conjunction with the neurotrophic factor BNDF and NOG gene for induction of neuroblasts to mature neurons. We express these genes using CRISPR-Cas9 gene editing technique which is directed to a DNA sequence by a single guide (gRNA). To target each gene, we inject using AAV-sgRNA, a gRNA per gene, with repeats if needed [[1]](#footnote-1). In order to use a light-activated CRISPR-Cas9 effector system, we fuse the light-inducible heterodimerizing proteins CRY2 and CIB1 from *Arabidopsis Thaliana* to the SPH transaction domain and either the N- or C- terminus of dCas9. SunTag-p65-HSF1 (SPH) compared to VP64 is an improved transaction domain and if we are unable to construct it, we will fall back to the CRY2-VP64 construct. To improve the system’s efficiency, we may have to fuse CIBN to both ends of dCas9. Then in presence of blue light (450 nm), CRY2 undergoes a conformational change that enables heterodimerization with CIBN, 3) SPH colocalizes with dCas9 via CRY2-CIBN interactions and induces transcription of SOX2, BNDF and Noggin proteins. We will also target NeuroD1 as Guo et Al. showed that NeuroD1 expression reprograms reactive astrocytes and N2 cells directly into fully functional neurons (glutamatergic and GABAergic neurons) without them going through a neuroprogenitor step (neuroblasts).

Main strategy: CRY2FL-SPH or CRY2PHR-SPH + CIBN-dCas9-CIBN or CIBN-dCas9 or dCas9-CBIN

To make the rest of our study easier, we engineer SPH-CRY2-CBIN astrocyte mice.

Non-viral mRNA delivery systems have recently show promising results with biodegradable ionizable lipid nanoparticles (LNPs) encapsulating mRNA (refs); however, lentivirus and adeno-associated viruses (AAV) have repetitively successfully been used to deliver CRISPR/Cas9 to modify cells both in vitro and in-vivo. DNA-based replication of these viruses can result in random integration into the host and has potential genotoxicity and oncogenesis. To address those concerns, we use Sendai virus (SeV) to encode our CRISPR-Cas9 constructs for delivery. Sendai virus is an RNA virus with no DNA intermediate and no nuclear phase, eliminating the risk of unwanted integration[[2]](#footnote-2).

Lastly, we use various fluorescent proteins for imaging and transgenic mice to validate our strategy with details provided in the validation section.  
To sum up our main injection strategy:

CRY2FL-SPH or CRY2PHR-SPH

+ SeV-CIBN-dCas9-CIBN or SeV-CIBN-dCas9 or SeV-dCas9-CBIN, and SeV-sgRNAs[[3]](#footnote-3)

For brain trauma animal model, we use controlled cortical impact injury (CCI) which allows fine control of the impact (time, velocity, depth) and lateral fluid percussion injury animal (LFPI) models.

The reasons to use two TBI models, is to study cell reprograming in regard to the type of injury: rigid with skull fracture, and mild-repetitive injuries simulating concussions like the ones observed in some sports and for different age-groups (it has been established that brain injuries in young and older people are more fatal). For every Tg mice we will need to recreate these two groups.

For this purpose, we will have two experimental groups: strong concussions using CCI (SCONC), mild concussion using LFPI (MCONC) and within each group: young, mid-age, and older mice. After TBI, we will wait few days for recovery leaving enough time for astrocytes, and N2 cells to be activated and proliferate in the injury site (5 days is the critical time point after which, literature has shown, more significant functional improvements are observed).

First, we use GFP reporter protein under human astrocyte marker hGFAP in hGFAP-Cre mice to determine the percentage of astrocytes present after the injury. We should

https://www-ncbi-nlm-nih-gov.proxy1.library.jhu.edu/books/NBK299210/#ch42\_sec2

<https://www.vectorbiolabs.com/product/vb2701-aav-with-cag-promoter-driven-hchr2h134r-mcherry/>

AAV=CAG-hChR2-mCherry

Construct of CRY2-SPH

oFMRI

list of TFs

1. In past studies, expression of a single gRNA is not sufficient to induce gene expression and co-transfection up to four gRNAs per gene has led to synergistic effects with an increase of gene expression. [↑](#footnote-ref-1)
2. In the context of a purely RNA-dependent replication, we may have to flank the gRNAs by self-cleaving ribozyme replicates. [↑](#footnote-ref-2)
3. If we cannot use SeV dCas9 and sgRNAs, we will revert back to AAV. [↑](#footnote-ref-3)